Division of Cardiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
J Am Coll Cardiol. 2010 Oct 19;56(17):1366-75. doi: 10.1016/j.jacc.2010.03.097.
This study sought to evaluate the long-term safety and effectiveness of percutaneous coronary intervention (PCI), as compared with coronary artery bypass grafting (CABG), for unprotected left main coronary artery (LMCA) disease.
Data on the long-term (beyond 5-year) comparative results of treatment of unprotected LMCA disease with stent implantation or CABG are limited.
We performed a 10-year clinical follow-up of 350 patients with unprotected LMCA disease who underwent PCI with bare-metal stents (BMS) (n = 100) or CABG (n = 250) from January 1995 to April 1999, and 5-year clinical follow-up of 395 patients with unprotected LMCA disease who underwent PCI with drug-eluting stents (DES) (n = 176) or CABG (n = 219) from January 2003 to May 2004. The primary safety end points were all-cause mortality and the composite of death, Q-wave myocardial infarction (MI), or stroke, and the primary efficacy end point was target vessel revascularization (TVR).
In the 10-year follow-up cohort of BMS and concurrent CABG, the adjusted risks of death (hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.44 to 1.50; p = 0.50) and the composite of death, Q-wave MI, or stroke (HR: 0.92; 95% CI: 0.55 to 1.53; p = 0.74) were similar between the 2 groups. The rate of TVR was significantly higher in the group that received BMS (HR: 10.34; 95% CI: 4.61 to 23.18; p < 0.001). In the 5-year follow-up cohort of DES and concurrent CABG, there was no significant difference in the adjusted risk of death (HR: 0.83; 95% CI: 0.34 to 2.07; p = 0.70) or the risk of the composite outcome (HR: 0.91; 95% CI: 0.45 to 1.83; p = 0.79). The rates of TVR were also higher in the DES group than the CABG group (HR: 6.22; 95% CI: 2.26 to 17.14; p < 0.001).
For the treatment of unprotected LMCA disease, PCI with stent implantation showed similar long-term mortality and rates of death, Q-wave MI, or stroke. However, stenting, even with DES, was associated with higher rates of repeat revascularization than was CABG.
本研究旨在评估经皮冠状动脉介入治疗(PCI)与冠状动脉旁路移植术(CABG)治疗无保护左主干冠状动脉(LMCA)疾病的长期安全性和有效性。
目前关于无保护 LMCA 疾病采用支架植入或 CABG 治疗的长期(5 年以上)比较结果的数据有限。
我们对 1995 年 1 月至 1999 年 4 月接受裸金属支架(BMS)(n=100)或 CABG(n=250)治疗的 350 例无保护 LMCA 疾病患者进行了 10 年临床随访,对 2003 年 1 月至 2004 年 5 月接受药物洗脱支架(DES)(n=176)或 CABG(n=219)治疗的 395 例无保护 LMCA 疾病患者进行了 5 年临床随访。主要安全性终点为全因死亡率和死亡、Q 波心肌梗死(MI)或卒中的复合终点,主要疗效终点为靶血管血运重建(TVR)。
在 BMS 和同期 CABG 的 10 年随访队列中,两组间死亡(风险比[HR]:0.81;95%置信区间[CI]:0.44 至 1.50;p=0.50)和死亡、Q 波 MI 或卒中的复合终点(HR:0.92;95% CI:0.55 至 1.53;p=0.74)的调整风险相似。接受 BMS 治疗的患者 TVR 发生率显著较高(HR:10.34;95% CI:4.61 至 23.18;p<0.001)。在 DES 和同期 CABG 的 5 年随访队列中,死亡风险(HR:0.83;95% CI:0.34 至 2.07;p=0.70)或复合结局风险(HR:0.91;95% CI:0.45 至 1.83;p=0.79)的调整风险无显著差异。DES 组的 TVR 发生率也高于 CABG 组(HR:6.22;95% CI:2.26 至 17.14;p<0.001)。
对于无保护 LMCA 疾病的治疗,支架植入 PCI 的长期死亡率和死亡、Q 波 MI 或卒中发生率相似。然而,支架置入术,即使采用 DES,其再次血运重建的发生率也高于 CABG。